Paul F Fitzpatrick

US Patent:

6441135, Aug 27, 2002

Filed:

Feb 11, 2000

Appl. No.:

09/381488

Inventors:

Michael C. Kiefer - Clayton CA
Paul A. Fitzpatrick - Albany CA
Helen L. Gibson - Oakland CA
Philip J. Barr - Oakland CA

Assignee:

Tanox, Inc. - Houston TX

International Classification:

C07K 100

US Classification:

530350, 530300, 435 71, 435 691, 536 231

Abstract:

The present invention provides polynucleotide sequences (bbp) encoding a Bak Binding Protein (BBP) and fragments thereof that bind to Bak. The invention also provides a BBP which binds to Bak. The invention also provides recombinant host cells containing polynucleotides encoding BBP. The invention further provides antibodies that specifically bind to BBP. The invention further provides methods for detecting agents such as drugs that alter the binding of a BBP with a Bak protein. The invention neither provides methods for detecting the presence of bbp or BBP in a biological sample, and further provides methods for modulating the levels of BBP in a cell. This invention additionally encompasses novel peptides, designated the âBBP Binding Domainsâ and the respective nucleotides, designated âbbpbd-1â and âbbpbd-2â which arc involved in the interaction between Bak and BBP.

US Patent:

6569661, May 27, 2003

Filed:

Nov 9, 2000

Appl. No.:

09/711202

Inventors:

Minmin Qin - Pleasanton CA
Lin Chen - San Francisco CA
Paul A. Fitzpatrick - Albany CA
John M. Hendstrand - Davis CA
Dan J. Wendt - Walnut Creek CA
Gary N. Zecherle - Novato CA
Christopher M. Starr - Sonoma CA
Emil D. Kakkis - Novato CA

Assignee:

BioMarin Pharmaceutical Inc. - Novato CA

International Classification:

C12Q 100

US Classification:

435200, 435 4, 435183, 530350, 530412, 530416

Abstract:

The present invention provides a recombinant human -L-iduronidase and biologically active fragments and mutants thereof, large scale methods to produce and purify commercial grade recombinant human -L-iduronidase enzyme as well as methods to treat certain genetic disorders including -L-iduronidase deficiency and mucopolysaccharidosis I (MPS 1).

US Patent:

6866844, Mar 15, 2005

Filed:

Nov 7, 2002

Appl. No.:

10/290908

Inventors:

Minmin Qin - Pleasanton CA, US
John M. Henstrand - Davis CA, US
Gary N. Zecherle - Novato CA, US
Dan J. Wendt - Walnut Creek CA, US
Lin Chen - San Francisco CA, US
Paul A. Fitzpatrick - Albany CA, US
Christopher M. Starr - Sonoma CA, US

Assignee:

Biomarin Pharmaceutical Inc. - Novato CA

International Classification:

A61K038/46
C12N009/16
C12N001/20
C12N015/00
A23J001/00

US Classification:

424 946, 435196, 4352523, 4353201, 435536, 435 232, 435530, 435412

Abstract:

The present invention provides a highly purified recombinant human precursor N-acetylgalactosamine-4-sulfatase and biologically active mutants, fragments and analogs thereof as well as pharmaceutical formulations comprising highly purified recombinant human precursor N-acetylgalactosamine-4-sulfatase. The invention also provides methods for treating diseases caused all or in part by deficiencies in human N-acetylgalactosamine-4-sulfatase including MPS VI and methods for producing and purifying the recombinant precursor enzyme to a highly purified form.

US Patent:

6972124, Dec 6, 2005

Filed:

Nov 7, 2003

Appl. No.:

10/704365

Inventors:

Minmin Qin - Pleasanton CA, US
Gary N. Zecherle - Novato CA, US
Paul A. Fitzpatrick - Albany CA, US
John M. Henstrand - Oakland CA, US
Dan J. Wendt - Walnut Creek CA, US
Lin Chen - San Francisco CA, US
Christopher M. Starr - Sonoma CA, US

Assignee:

BioMarin Pharmaceuticals Inc. - Novato CA

International Classification:

A61K038/46
C12N009/16
C12N001/20
C12N005/00
A23J001/00

US Classification:

424 946, 435196, 4352523, 4353201, 536 232, 530412

Abstract:

The present invention provides a highly purified recombinant human precursor N-acetylgalactosamine-4-sulfatase and biologically active mutants, fragments and analogs thereof as well as pharmaceutical formulations comprising highly purified recombinant human precursor N-acetylgalactosamine-4-sulfatase. The invention also provides methods for treating diseases caused all or in part by deficiencies in human N-acetylgalactosamine-4-sulfatase including MPS VI and methods for producing and purifying the recombinant precursor enzyme to a highly purified form.

US Patent:

7316915, Jan 8, 2008

Filed:

Jul 1, 2002

Appl. No.:

10/189294

Inventors:

Michael C. Kiefer - Clayton CA, US
Paul A. Fitzpatrick - Albany CA, US
Helen L. Gibson - Oakland CA, US
Philip J. Barr - Oakland CA, US

Assignee:

Tanox, Inc. - Houston TX

International Classification:

C12P 21/06

US Classification:

435 691, 435 6, 435 71, 530350

Abstract:

The present invention provides polynucleotide sequences (bbp) encoding a Bak Binding Protein (BBP) and fragments thereof that bind to Bak. The invention also provides a BBP which binds to Bak. The invention also provides recombinant host cells containing polynucleotides encoding BBP. The invention further provides antibodies that specifically bind to BBP. The invention further provides methods for detecting agents such as drugs that alter the binding of a BBP with a Bak protein. The invention further provides methods for detecting the presence of bbp or BBP in a biological sample, and further provides methods for modulating the levels of BBP in a cell. This invention additionally encompasses novel peptides, designated the “BBP Binding Domains” and the respective nucleotides, designated “bbpbd-1” and “bbpbd-2” which are involved in the interaction between Bak and BBP.

US Patent:

7531341, May 12, 2009

Filed:

Jun 12, 2006

Appl. No.:

11/451999

Inventors:

Michel Claude Vellard - Corte Madera CA, US
Paul Andrew Fitzpatrick - Albany CA, US
Emil D. Kakkis - Novato CA, US

Assignee:

BioMarin Pharmaceutical Inc. - Novato CA

International Classification:

C12N 9/88
A61K 38/00

US Classification:

435232, 530345

Abstract:

The present invention is directed to phenylalanine ammonia lyase (PAL) produced by prokaryotes, wherein such prokaryotic PAL wherein the PAL variant has a greater phenylalanine-converting activity as compared to a wild-type PAL. The invention thus provides compositions of bacterial PAL and biologically active fragments, mutants, variants and analogs thereof, as well as methods for the production, purification, and use of such compositions for therapeutic and industrial purposes.

US Patent:

7534595, May 19, 2009

Filed:

May 25, 2007

Appl. No.:

11/807227

Inventors:

Michel Claude Vellard - Larkspur CA, US
Paul Andrew Fitzpatrick - Albany CA, US
Emil D. Kakkis - Novato CA, US
Daniel J. Wendt - Walnut Creek CA, US

Assignee:

BioMarin Pharmaceutical Inc. - Novato CA

International Classification:

C12N 9/88
A61K 38/00

US Classification:

435232, 530345, 514 12

Abstract:

The present invention is directed to phenylalanine ammonia-lyase (PAL) produced by prokaryotes, wherein such prokaryotic PAL wherein the PAL variant has a greater phenylalanine-converting activity and/or a reduced immunogenicity as compared to a wild-type PAL. The invention thus provides compositions of bacterial PAL and biologically active fragments, mutants, variants and analogs thereof, as well as methods for the production, purification, and use of such compositions for therapeutic and industrial purposes.

US Patent:

7537923, May 26, 2009

Filed:

Apr 22, 2008

Appl. No.:

12/107736

Inventors:

Emil D. Kakkis - Novato CA, US
Paul A. Fitzpatrick - Albany CA, US
Daniel J. Wendt - Walnut Creek CA, US
Sean M. Bell - San Rafael CA, US
Augustus O. Okhamafe - Concord CA, US

Assignee:

BioMarin Pharmaceutical Inc. - Novato CA

International Classification:

C12N 9/88
A61K 38/00

US Classification:

435232, 530345

Abstract:

The present invention is directed to phenylalanine ammonia-lyase (PAL) variants produced by prokaryotes, wherein such prokaryotic PAL variant has a greater phenylalanine-converting activity and/or a reduced immunogenicity as compared to a wild-type PAL. The invention provides compositions of prokaryotic PAL and biologically active fragments, mutants, variants or analogs thereof, as well as methods for the production, purification, and use of such compositions for therapeutic purposes, including the treatment of cancer.